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ABSTRACT
 Alzheimer’s Disease (AD) is a neurodegenerative disorder and the most common form 
of dementia, with symptoms and manifestations that progressively get worse with increasing 
age. Therefore, with the ageing of the population worldwide, the prevalence of AD is increas-
ing. There is no current cure for AD and, as a result, there has been a recent rise in interest in 
plant bioactive compounds that may prevent or improve symptoms of the disease. Currently, the 
nootropic potential of plant derived compounds that can combat damage posed by free radicals 
is being investigated. Antioxidants, in particular, the Green Tea Catechins (GTC), have been 
shown significant interest due to their exceptionally strong antioxidant and anti-inflammatory 
properties. The aim of this paper was to perform a systematic review based on the PRISMA 
guidelines in order to evaluate the effectiveness of GTC as a potential treatment to suppress 
or delay the onset of AD in pre-clinical animal trials. The paper reports on three animal pre-
clinical trials in which rat or mice models of AD were used to test the effects of GTC or the pure 
form of the predominant GTC, Epigallocatechin gallate (EGCG), administered orally or by 
injection. The reviewed papers show that GTC extracts or pure EGCG had preventative effects 
on AD in the various animal models used, including the enhancement of learning and memory, 
possibly through the reduction in oxidative stress, β-amyloid plaque build up and Tau protein 
phosphorylation. Therefore, GTC extracts or EGCG in its pure form may serve as nootropic 
options in the prevention or treatment of neurodegeneration-associated diseases such as AD. 
KEYWORDS: Green Tea Catechins; EGCG; Oxidative stress; Neuroprotection; Pre-clinical 
animal trials; Alzheimer’s disease; Beta amyloids; Tau protein.
ABBREVIATIONS: AD: Alzheimer’s Disease; GTC: Green Tea Catechins; LPO: Lipid peroxides; 
ROS: Reactive Oxygen Species; EGCG: Epigallocatechin gallate; MPTP: N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine; EGC: Epigallocatechin; ECG: Epicatechin gallate; TBARS: 
Thiobarbituric acid-reactive substances; SOD: Superoxide dismutase; IP: Intraperitoneal; 
RAWM: Radial Arm Water Maze; FRAP: Ferric Reducing Ability of Plasma; APP: Amyloid 
Precursor Protein.
INTRODUCTION
 Mental disease represents one of the world’s leading disabilities affecting over 25% 
of people at some period during their lifetime. In 2004, it represented 13% of the global burden 
of disease and it is proposed to increase to 15% by the year 2020, which will place it as the 
second leading cause of disability in the world.1,2 Alzheimer’s Disease (AD) and cognitive im-
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pairment are on the increase and have been identified as contrib-
uting to the overall increase in mental disease, which indicates 
an increasing prevalence of disorders of later life rather than of 
childhood.3-5 The increasing incidence of these types of mental 
disease can also be viewed as being due to the rapid ageing of 
the world’s population and the fall in the birth rate, which has 
resulted in an overall lower prevalence of the types of mental 
disease associated predominately with adolescence.6 
 Much of the scientific research in the elderly has been 
devoted to studies on the implications of the cognitive decline 
and impairment that characterise the dementive-type illnesses. 
Dementia is a disease of the brain, and the term “dementia” is 
classified as an “umbrella” term for various types of diseases. 
These are characterised by the development of multiple cogni-
tive impairments that can arise due to different causes such as 
direct physiological effects of a medical condition, persisting 
effects of substance abuse or multiple other aetiologies. There-
fore, there are various types of dementia such as dementia of the 
Alzheimer’s type, vascular dementia and dementia due to vari-
ous diseases such as HIV and Parkinson’s disease.7,8 It is also 
important to note that the aetiology of certain types of multiple 
cognitive deficits cannot be identified and thus, “Dementia Not 
Otherwise Specified” is another type of this disease.7
 Studies have identified dementia of the Alzheimer’s 
type to be the most prevalent form of dementia.9,10 The AD de-
mentia has therefore become the most well-known type of de-
mentia chiefly associated with older age.7,11,12 
 The onset of AD is categorised by two subtypes accord-
ing to age: early onset AD where symptoms of this type of de-
mentia manifest themselves before 65 years of age and late onset 
AD with symptoms emerging after the age of 65.7 The use of 
65 as the age cut-off point is completely arbitrary from a health 
point of view as it does not have any medical significance.13 Ob-
viously however, it is related to the age that is normally associ-
ated with retirement from work. 
 The behavioural and cognitive onset of AD can be slow 
and gradual; it predominately manifests itself as a slow but pro-
gressive cognitive decline.7 Furthermore, there is no one univer-
sally accepted neuropathologic criteria to differentiate AD from 
healthy brain ageing primarily because AD is a complex neuro-
degenerative dementing illness.14-16 However, the fundamental 
neuropathologic features of AD, based on the post-mortem ex-
amination of patients’ brains, include reduced brain volume, en-
larged ventricular spaces, region specific neurofibrillary tangles 
and neuritic amyloid plaques.17,18 The exact causative factor for 
these brain changes still remains unknown. However, the final 
resulting physiological outcome is death of neural cells which 
causes severe cognitive impairment and eventually death of the 
patient suffering from AD.11,13,15,16
 It has been proposed that death of the neural cells is a 
result of a cascade of intracellular and extracellular events.16,17 
There are several different factors which have been postulated 
to directly or indirectly play important roles in the initiation of 
these events: oxidative damage,19,20 genetic polymorphisms,21,22 
gene mutations23 and abnormal levels of β-amyloid and tau pro-
teins.24 Of these, the deposition of β-amyloid protein is seen as 
the primary event in the pathogenesis of AD. The other changes 
such as neurofibrillary tangles, synaptic degeneration and neu-
ronal cell death are proposed to arise only as a consequence of 
the deposition of this protein in the brain.25
 In addition, neurodegeneration is a common feature of 
AD with the main reasons described to be the combination of 
multi-factorial events such as neuro-inflammation, glutamate 
rich excitotoxicity and depletion of antioxidants.26 Hence, in re-
cent years there has been developing evidence proposing that 
dietary polyphenols can potentially counteract and suppress the 
neuronal injury.26-29
 Polyphenols are ubiquitous compounds classified 
as wide and complex group of plant secondary metabolites 
and to date there have been over 8000 compounds identified. 
Additionally, these compounds are exceptionally diverse in 
their structures, ranging from very simple molecules (pheno-
lic acids) to more complex and highly polymerized structures 
(proanthocyanidins).30-36 The polyphenols are generally divided 
into two groups based on their molecular weight, low (500-3000 
Da) and high molecular weight (>3000 Da).37 In addition, these 
compounds can also be classified into different groups based on 
the number of phenolic rings that they contain and on the basis 
of the structural elements by which these rings are connected to 
one another. They include such compounds as phenolic acids, 
flavonoids, stilbenes and lignans (Figure 1). 
 One of the foods rich in bioactive compounds, particu-
larly flavonoids, is green tea (Camellia sinensis). In recent years, 
there has been a significant upward trend in the consumption of 
green tea and taking into consideration that overall tea (black 
and green) is one of the most consumed beverages in the world, 
it is not surprising that this trend was closely followed by aca-
demic research interest. 
 The most abundant polyphenolic compounds in green 
tea are the catechins, which account for nearly 30% of the dry 
tea leaf weight.38 In the recent literature, the Green Tea Cat-
echins (GTC) have been related to a variety of different ben-
eficial health effects particularly with respect to their potential 
for preventing and treating different cancers,39,40 cardiovascular 
diseases,41-43 inflammatory diseases44-47 and some of the neurode-
generative diseases45,48,49 in humans. Accounting for at least half 
of the total GTC,38 the most predominant catechin found in green 
tea is Epigallocatechin gallate (EGCG), which has been ascribed 
numerous beneficial properties including antioxidant,50 anti-
inflammatory,51,52 anti-microbial53,54 and anticancer effects.55-57 
 Although current trend in the scientific writing of sys-
tematic reviews is chiefly reserved for trials with human subjects 
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from various cohorts, the use of well-designed pre-clinical ani-
mal trials is gaining value. This is primarily due to the increased 
number of well-developed gene-knockout animal models that 
can be used to mimic certain diseases commonly occurring in 
humans. Additionally, some of the illnesses such as AD can only 
be successfully diagnosed post-mortem. Therefore, keeping in 
mind that findings from animal models are not necessarily di-
rectly transferrable to humans, these studies still provide valu-
able insight into the potential mechanisms of action that may be 
applied to clinical research in humans. Therefore, the aim of this 
systematic review is to look into what is known about the rela-
tionship between GTC and the leading biomarkers associated 
with the development of AD.
METHODS
Animals
 The animals used as models in the pre-clinical animal 
studies covered in this systematic review were rodents in par-
ticular rats (JCL: Wistar) and mice (C57/BL; Tg2576; APPsw; 
non-transgenic). 
Search Strategy
 The standardized criteria for conducting and reporting 
systematic reviews of observational studies based on the PRIS-
MA 2009 guidelines58 were used. The search strategies were 
applied for articles published since the year 2000 using the fol-
lowing electronic databases: PubMed (http://www.ncbi.nlm.nih.
gov/pubmed/), the Cochrane Library (http://www.thecochraneli-
brary.com/view/0/index.html), and Scopus (http://www.elsevier.
com/online-tools/scopus). Titles and abstracts were scanned for 
relevance and appropriate articles were selected.
 The search used terms relating to the topic of this 
systematic review; “Green tea polyphenols” and “Alzheimer’s 
Disease” were used in the primary search followed by “Beta 
Amyloid”, “Neuroprotection” and “Catechins” in the secondary 
search. In addition, reference list checks of selected articles with 
relevance to the topic were also performed. 
Selection Criteria
 For the purpose of this systematic review, articles were 
selected only if they were entirely published in English, in peer-
reviewed journals and were identified as pre-clinical animal tri-
als. They were included if GTC were delivered as a part of a 
supplement, injection, oral consumption in tea, water, food or 
similar delivery methods. Furthermore, studies selected for re-
view had sample sizes of over 5 animals (at the end of the study) 
of any gender and had identified looking at whether or not GTC 
affected one or all of the biomarkers in relation to the develop-
ment and onset of AD.
Primary Outcomes
 The primary outcomes were cognitive learning and ab-
normal levels of β-amyloid and tau proteins in brain homoge-
nates.
Secondary Outcomes
 The secondary outcomes were oxidative stress identifi-
cation by the presence of Lipid peroxide (LPO) by-products and 
generation of Reactive Oxygen Species (ROS). 
Figure 1: Brief representation of the polyphenols classification with focus on green tea catechins.
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Materials
 Studies used green tea extracts, GTC or pure EGCG 
in the intervention and the control groups were always admin-
istered with water containing no additional compounds or in a 
case of injections, animals were injected Intraperitonealy (IP) 
with sterile saline or not injected at all.
RESULTS
Characteristics of the Studies
 Preliminary searches of the selected databases identi-
fied 4635 records with the terms “Green tea polyphenols” and 
“Alzheimer’s disease” alone (Figure 2) but the secondary search 
reduced this to 500 articles. These 500 abstracts were screened, 
of which only 3 studies (1 in rats and 2 in mice) were included 
in the review because they fitted all the eligibility criteria.59-61 
These 3 articles were published after the year 2000; included 
animals in the pre-clinical setting treated orally or injected with 
a GTC supplement or an individual purified catechin and also 
included control groups.
GTC or EGCG Supplementation Doses
 The 3 articles included in this review utilized either 
a GTC preparation or pure EGCG as the treatment method in 
animals. In the study with rats,59 the animals were orally treated 
with an aqueous GTC extract, referred to as Polyphenon E (Mi-
tusi Norin CO. Ltd, Tokyo, Japan), which had an initial concen-
tration of total catechins of 0.5% (w/v). The extract was diluted 
daily in the animals’ drinking water to provide the following 
concentrations of the individual catechins: EGCG (63%); EC 
(11%); EGC (6%) and ECG (6%). The control group received 
drinking water with no catechins in it.
 One of the 2 studies in mice60 also used a GTC pow-
dered extract (Plant extract GmbH & Co, KG, Vestenbergs-
greuth, Germany) in which the catechin concentration was said 
to vary between 12 and 17% (w/w). In this study, some mice 
were IP injected with 0.5, 1 or 5 mg/kg of the GTC extract in 
saline (twice on the first day of the experiment with a 6 hr in-
terval) followed by once for the next 4 days. Control mice were 
injected with saline. In the same paper, other mice received oral 
treatment with pure EGCG at two concentration levels (2 and 10 
mg/kg/day) for 14 days. 
 In the other mice study,61 some of the animals (Tg2576 
females) were orally administered with pure EGCG (50 mg/kg) 
in water or water only (control) on a daily basis for 6 months. 
Other mice (female APPsw) were treated by IP administration of 
EGCG (20 mg/kg) or vehicle only (control) daily for 60 days. 
Cognitive Testing
 Rats were tested for learning-related cognitive ability 
with the use of the eight-arm radial maze with a particular focus 
on the reference memory error and working memory error.59 The 
Figure 2: Flow chart of the publication selection process.
ADVANCES IN FOOD TECHNOLOGY AND
NUTRITIONAL SCIENCES
Open Journal
http://dx.doi.org/10.17140/AFTNSOJ-1-108
Adv Food Technol Nutr Sci Open J
ISSN 2377-8350
Page 52
Radial Arm Water Maze (RAWM) was also used to assess the 
experimental mice for working memory.61 
Induction of Cognitive Deficits/Mimicking of Ad Symptoms in 
Animals
 One of the mice studies included “Swedish” mutant 
amyloid precursor protein overexpressing (APPsw, Tg) mice,61 
while the other study injected the mice IP with N-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine (MPTP) at levels of 24 mg/kg/
day in order to replicate the clinical AD symptoms.60 However, 
in the Wistar rat study, the animals were infused with Aβ1-40 (4.9-
5.5 mmol/l) into the exposed left ventricle after the injection of 
AlCl3 (0.5 µg) was performed in the right ventricle.
59 
Tissue Analysis/Testing
 In the mice studies, the brain homogenate tissues were 
analyzed using Western blots and immunohistochemistry tech-
niques with a specific focus on soluble Aβ1-40
61 and tyrosine hy-
droxylase.60 In the rat study,59 plasma and brain homogenates 
were tested for LPO concentrations using the Thiobarbituric 
acid-reactive substances (TBARS) assay while plasma was also 
analyzed for total antioxidant activity using the Ferric Reduc-
ing Ability of Plasma (FRAP) assay and for plasma triglycerides 
and total cholesterol using commercially available enzyme kits.
Study Outcomes
 One of the studies by Rezai-Zadeh, et al.61 was done to 
determine if the oral administration of ECGC would cause a re-
duction in plaque build-up in the APPsw mice. It was found that 
the ECGC (50 mg/kg) treated mice had significantly reduced 
(p<0.05) plaque build-up compared to controls (Table 1). This 
was supported by the micrographs of the brain sections where 
it was identified that β-amyloid stained antibody sections were 
substantially reduced in the cingulate and entorhinal cortex, as 
well as in the hippocampus by 54%, 51% and 43%, respectively. 
This was further supported by analysis of the anterior quarter 
brain homogenates, which indicated that the oral consumption 
of EGCG significantly (p<0.05) decreased both the soluble and 
insoluble forms of β-amyloid plaques.61 In addition, the Tau pro-
tein formation induced by the deposition of β-amyloid plaques 
was also suppressed in the EGCG treated mice.
 The second study by Rezai-Zadeh, et al.61 was done to 
examine whether EGCG had potential cognitive benefits, either 
by IP injection or by oral intake (Table 1). The results identi-
fied that the animals, after two months of IP injections with 
EGCG, had an improved working memory compared to the 
controls (p<0.001). This was supported during the final stage of 
the RAWM testing where the EGCG treated transgenic animals 
showed improvements between the trials while the control non-
transgenic mice showed no working memory improvements. A 
similar finding was also identified for animals that consumed the 
EGCG orally (50 mg/kg); the transgenic mice were not weak-
ened in working memory compared to the non-transgenic con-
trol animals.
 The study by Haque, et al.59 in JCL: Wistar rats was 
focused on the effects of GTC on three measures: AD precur-
sors/indicators, plasma and brain tissue (hippocampal and cere-
bral cortex) oxidative stress and outcomes of the eight arm ra-
dial maze test (working and reference memory errors) (Table 1). 
The plasma TBARS concentrations were significantly (p=0.02) 
higher in the control rats infused with the vehicle only and in 
rats infused with Aβ1-40, whether they were pre-administered 
with Polyphenon E or not, compared to the animals infused with 
Polyphenon E only. However, the plasma FRAP was signifi-
cantly (p<0.0001) higher in the Polyphenon E pre-administered 
groups, compared to controls, whether they were infused with 
Aβ1-40 or not. Furthermore, the plasma cholesterol levels were 
significantly (p<0.05) lower in the polyphenon E treated Aβ1-40 
infused group compared to the rest of the experimental groups 
although the plasma triglycerides were not significantly (p>0.05) 
different amongst the groups.
 The hippocampal TBARS concentrations were signifi-
cantly (p<0.0001) lower as were the ROS levels (p=0.0029) in 
the Aβ1-40 infused rats pre-administered with Polyphenon E. The 
cerebral cortex TBARS concentrations were unaffected (p=0.2) 
amongst the groups but the Polyphenon E only group (no Aβ1-40 
infused) had significantly (p<0.05) lower concentrations of ROS 
compared to the other groups.
 The subset analysis of the number of radial maze error 
scores also indicated that Polyphenon E has significant effects 
in both the vehicle only and Aβ1-40 infused rats. The Polyphenon 
E pre-treated groups had significantly (p<0.0001) lower error 
scores than either the Aβ1-40 infused or vehicle treated animals.
 The study by Levites, et al.60 investigated the neuropro-
tective properties of a GTC extract and pure EGCG in the MPTP 
mice model of dopaminergic neurodegeneration similar to that 
found in sufferers of Parkinson’s disease (Table 1). In this study, 
it was identified that pre-treatment of the mice with either GTC 
at two doses (0.5 and 1 mg/kg) or with pure EGCG at two doses 
(2 and 10 mg/kg) prevented the neuronal losses caused by the 
MPTP treatment and concomitantly prevented the depletion of 
dopamine and tyrosine hydroxylase in the substantia nigra of the 
mice’s brains. It was identified that the GTC extract provided 
significant protection against the MPTP induced decrease in the 
melanin containing dopamine neurons at the GTC doses of 0.5 
and 1 mg/kg although the higher dose of 5 mg/kg GTC was not 
effective. In addition, the pure EGCG at 2 and 10 mg/kg also 
considerably prevented the decrease in striatal dopamine neu-
rons induced by the MPTP.
 Furthermore, the activities of the SOD and catalase en-
zymes were assessed in the striatum of the mice treated with 
EGCG, MPTP or both of these compounds. It was observed that 
the MPTP increased the activity of both of these enzymes while 
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Author (Year) Animals, sample size, age Aim Intervention Results 
Rezai-Zadeh, 
et al. (2008) 
Female “Swedish” mutant amy-
loid precursor protein overex-
pressing (APPsw) 
(All n=10; C:n=5; T:n=5)
Female Tg2576 
(All n=10; C:n=5; T:n=5) 
Female Non-transgenic mice 
(n=5)
Age at start: 8 mth.
Anti-amyloidgenic ef-
fects of orally adminis-
tered EGCG in APPsw 
mice. 
Oral EGCG (50mg/kg) or control  
(water) treated for 6 mth. 
Treatment resulted in a significant reduc-
tion in plaque buildup (p>0.05)
Treatment decreased soluble and insolu-
ble forms of Aβ
1-40,42
, increased ADAM10 
maturation and increased sAAP-α release 
(p<0.001)
Provision of comparable attenuation of 
amyloid pathology to that of IP injections. 
Effect of IP injection 
EGCG treatment on 
Tau protein physiology 
in APPsw mice
Treated 2 months with IP injec-
tion of pure EGCG (20mg/kg) or 
orally consumed EGCG (50mg/kg).  
Control group did not receive any 
treatment. 
Both treatments (oral and IP injection) 
decreased Tau hyperphosphorylation 
(p<0.001) 
Cognitive benefits af-
ter oral administration 
of EGCG in APPsw 
mice 
Animals provided with EGCG treatment 
had substantially improved working 
memory performance, comparable to non-
transgenic 
non-treated mice (p<0.001). 
Haque, et al. 
(2008) 
Male JCL:Wistar rats 
(All=49; C:n=25; T:n=24)
Age at start: 5 wk. 
Long-term administra-
tion of GTC and effect 
on oxidative stress 
and cognitive impair-
ment in Aβ
1-40
 infused 
AD rat model. 
Treatment group was administered 
GTC combination [EGCG (63%), 
EC (11%), EGC (6%) and ECG 
(6%)] in water for  26 wk. 
Treatment prevented β-amyloid associ-
ated impairment in cognitive learning 
(p<0.0001). 
Treated rats showed significant decreased 
number of reference and working memory 
errors (p<0.05). 
Treated rats also had lower LPO (TBARS) 
in hippocampus and plasma and ROS in 
hippocampus and cortex and higher FRAP 
in plasma. 
Levites, et al. 
(2001) 
Male C57/BL mice 
(All; n=144)
The effects of GTC 
extract in MPTP 
injected animals Mice were IP injected twice on the 
first day with GTC extract (0.5mg/
kg), followed by injection of MPTP 
(24mg/kg) and GTC extract (0.5mg/
kg) for the subsequent four days. 
For EGCG studies, mice were orally 
administered EGCG (2 or 10mg/kg/
day) for 10 days and then EGCG (2 
or 10mg/kg/day) and MPTP (24mg/
kg/day) for the following 4 days. 
Control mice received only saline or 
GTC extract 
The injected GTC extract and oral EGCG 
showed a protective effect against MPTP-
induced decreases in dopamine and ty-
rosine hydroxylase protein levels (p<0.05). 
The effect of EGCG 
on MPTP-induced 
neuro-degeneration 
The injected GTC extract also prevented 
the MPTP-induced decrease in dopamine 
neurons in the brains. 
(p<0.02). 
The prevention of 
the MPTP-induced 
increase in the 
antioxidant enzymes 
SOD and Catalase by 
EGCG. 
Oral EGCG at 2mg/kg/day, but not at 
10mg/kg/day, prevented the MPTP-in-
duced increase in SOD and Catalase. 
Table 1: Summary of GTC effects in animal pre-clinical trials.
pre-treatment with EGCG prevented these effects at 2 mg/kg but 
not at 10 mg/kg.
DISCUSSION
 The recent advances in drug development as well as 
more identifiable characteristics of neurodegeneration have set a 
path for the utilization of drugs that exhibit free radical scaveng-
ing and iron-chelating properties. These compounds can conse-
quently serve as potential treatment of neurodegeneration and 
act as vehicle mediated “backbones” for human trials on sup-
pressing the development of AD and Parkinson’s disease alike. 
The utilization of pure EGCG and more complex GTC mixtures 
in the prevention of neurodegeneration has been associated with 
the catechol-like structures as it is well established that catechol-
containing structures are potential antioxidants and free-radical 
scavengers.62,63 
 The studies outlined in this review have exemplified 
some of the putative neuroprotective properties that GTC ex-
tracts and pure EGCG have on the suppression of neurodegen-
eration and the preservation of learning and behavioral patterns 
commonly affected by AD. The studies reviewed identified the 
benefits of GTC on either the suppression of development or the 
maintenance of symptoms associated with AD.
 The study by Rezai-Zadeh, et al.61 identified that the 
oral administration of EGCG diminished amyloidosis in an AD-
induced animal model, which is readily identified as one of the 
hallmarks in the development of AD; EGCG reduced the forma-
tion of β-amyloid plaque in the primary neuronal cells.61,64 Pre-
vious studies have predicted and observed that EGCG promotes 
the cleavage of Amyloid Precursor Protein (APP) into soluble-
APP associated with an elevation of α-secretase cleavage, the 
main pathway for APP processing.65 Therefore, the findings by 
Rezai-Zadeh and colleagues61 indicate that EGCG may poten-
tially reduce the formation of the toxic sarkosyl soluble phos-
pho-tau isoforms that are considered to be one of the features of 
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AD.64 In this mouse study, both delivery methods of IP injection 
and oral consumption of EGCG also independently promoted 
benefits for cognition and learning by reducing the number of 
maze errors in the AD-induced animal model.61 
 Furthermore, in the same article,61 pure EGCG admin-
istration to amyloid precursor protein overexpressing (APPsw, 
Tg) transgenic mice, successfully reduced the development of 
the neuro-toxic portion of the Tau protein strands.66,67 The oral 
administration of EGCG for a six-month period to the AD trans-
genic mice also reduced β-amyloid deposition and its build up 
in important cognitive areas of the brain, improving working 
memory to near perfect results. Therefore, the findings of this 
study also supported the potential of EGCG to provide cognitive 
benefits in the transgenic mice models of AD as measured by 
RAWMS. Finally, these findings strengthen the possibility that 
the consumption of EGCG can be seen as a feasible therapeutic 
approach against AD and other similar cognitive impairments, 
which result from neuro-degeneration.
 The study by Haque, et al.59 demonstrated that the long 
term pre-administration of PolyphenonE could prevent the de-
velopment of β-amyloid-induced spatial cognitive learning dif-
ficulties in an AD rat model. In this model, the infusion of Aβ1-40 
into the rat’s hippocampus induced a deficit in long-term po-
tentiation and also in working memory. The β-amyloid infusion 
also increased hippocampal ROS concentrations, suggesting that 
ROS generation may lead to impaired learning cognitive func-
tions.
 The findings indicated that the neuroprotection and 
prevention of cognitive learning impairments seen with the 
GTC extract may have been due to its ability to decrease the 
β-amyloid induced oxidative stress.59 The pre-administration of 
PolyphenonE decreased the LPO (TBARS) and ROS concen-
trations, induced by β-amyloid infusion, in both the brain and 
plasma of the rats; the Polyphenon E also increased the FRAP 
in plasma. These results suggested that there was a significant 
and independent antioxidant effect of the GTC extract, which 
could potentially be harnessed to prevent cognitive damage in 
AD. This increase in antioxidant activity was proposed by the 
authors to be the main enhancing influence on the memory-re-
lated learning observed.59 These findings were also consistent 
with other observations that the oral consumption of GTC and 
other antioxidants is associated with the activation of antioxida-
tive enzymes in various mouse models.68-70
 In one part of the study in mice by Levites, et al.60 they 
utilized MPTP as an initiator of neuro-degeneration caused by 
depletion of dopamine and tyrosine hydroxylase and showed 
that a GTC extract could prevent the MPTP-induced decreases 
in dopamine and tyrosine hydrolase. In a further study using a 
mice model of cerebral ischemia, pure EGCG injected immedi-
ately after ischemia, resulted in less memory impairment and re-
duced hippocampal neuron damage. Levites Y, et al.60 suggested 
that the EGCG’s neuroprotective properties may also include the 
regulation of antioxidant enzymes.
 In conclusion, the papers reviewed in this systematic-
review indicate that GTC and/or pure EGCG possess neuropro-
tective properties, which may be useful for preventing the de-
velopment, or for the maintenance, of AD. Each of the papers 
reviewed also show effects on one or more of the current bio-
markers linked to the development of AD. Although the findings 
of these articles are associated with pre-clinical animal models, 
they never the less provide a “stepping stone” for the utilization 
of GTC or EGCG as nootropic nutraceuticals for the potential 
suppression of neurodegenerative diseases such as AD.
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